Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110

Heat Biologics Inc HTBX announced promising preclinical data regarding PTX-35. The data has been accepted for publication in the American Journal of Transplantation.

  • A single dose of the preclinical version of PTX-35 (mPTX-35) expanded regulatory T cells (Tregs) and significantly improved disease and graft survival outcomes.
  • Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted with beta-cell islet allografts and treated with mPTX-35.
  • Long-term surviving grafts showed a marked increase in Treg infiltration, directly correlated with mPTX-35 agonist activity. 
  • PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3).
  • Jeff Wolf, Chief Executive Officer, noted, "We are also making significant progress with HS-110 and expect to file for an End of Phase 2 meeting with the FDA this quarter. Our goal for this meeting is to discuss potential Phase 3 registration pathways for HS-110. Although this submission is taking longer than expected, we believe we have prepared a very comprehensive package and look forward to the FDA's feedback."
  • HS-110 (viagenpumatucel-L) is the Company's first biologic product candidate in a series of proprietary ImPACT based immunotherapies designed to stimulate a patient's T-cells to destroy cancer.
  • Price Action: HTBX shares are down 1.30% at $3.04 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!